Safety Profile Comparable to DA Therapy in Patients With AML-MRC and t-AML1

  • Adverse Events
  • Myelosuppression
  • Additional Safety Information

Comparable Overall Frequency and Severity of Grade 3–5 AEs vs DA Therapy2-5

Grade 3-5 AEs in ≥5% of older adults with high-risk AML2-5

Refer to section 4.8 of the Summary of Product Characteristics for full safety information3

Five patients experienced AEs that led to treatment discontinuation:2

  • Vyxeos Liposomal: Cardiac failure, cardiomyopathy, and acute renal failure in one patient each
  • Conventional chemotherapy: Decreased ejection fraction in two patients

Prolonged Myelosuppression vs DA Therapy3

Thrombocytopenia and neutropenia in older patients with AML-MRC and t-AML3

Vyxeos Liposomal is associated with prolonged thrombocytopenia and neutropenia vs DA therapy, so patients will require additional monitoring3

Hypersensitivity reactions3

Cardiotoxicity3

Explore the safety data from the real-world evidence studies in detail here

View

Discover how myelosuppression can be managed following Vyxeos Liposomal therapy

RELATED CONTENT

Vyxeos Liposomal delivers quadruple endpoint superiority vs DA 3+7

mOS – p=0.003 • Post-HSCT mOS – p=0.009 CR/CRi – p=0.016 • EFS – p=0.021

Discover more

Watch UK AML experts discuss the RWE of Vyxeos Liposomal from BSH ’22 on our interactive learning webpage

Watch now

ADVERSE EVENTS REPORTING

Adverse events should be reported. For the UK, reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/

For the Republic of Ireland, reporting forms and information can be found at: https://www.hpra.ie/homepage/about-us/report-an-issue

Adverse events should also be reported to Jazz Pharmaceuticals by phone: +44 8081890387 (UK toll-free) or +353 1 968 1631 (Republic of Ireland).

UK-VYX-2200068 | June 2022